榴莲视频

This cohort study assesses the validity of molecular targets and therapeutic benefits of US Food and Drug Administration (FDA)鈥揳pproved genome-targeted cancer drugs based on the outcomes of their corresponding pivotal clinical trials.

This Viewpoint encourages investigators to move beyond FDA guidance toward patient-centered therapies and health equity for BCG-unresponsive bladder cancer.

This cohort study assesses whether drugs with the most direct-to-consumer television advertising represent advances over existing treatments.

This cross-sectional study considers 18 top-selling drugs to demonstrate a new approach to improved estimation of Medicaid rebates to better understand trends in Medicaid and non-Medicaid spending and drug pricing.

This cohort study examines the characteristics of high-risk therapeutic devices approved by the US Food and Drug Administration for use in children and adolescents between 2016 and 2021.

This Viewpoint proposes restructuring the WHO Essential Medicines List to remove consideration of cost and cost-effectiveness from the expert committee reviews of clinical effectiveness, safety, and public health value, and chartering a new framework for pooled global negotiation and procurement of costly medicines included in the list.

This Viewpoint describes the provisions and limitations of prescription drug pricing reforms enacted by US Congress as part of the Inflation Reduction Act in August 2022.

This cohort study assesses the therapeutic value of drugs granted accelerated approval or conditional marketing authorization in the US and European Union from 2007 to 2021.

This economic evaluation study assesses the clinical benefit of novel drugs approved in 2018 and 2019 and examines whether drugs approved with special regulatory designations appear to provide meaningful therapeutic value.

This Viewpoint describes the therapeutic ratings and coverage decisions taken by key bodies across the US, Canada, and Europe.

This cross-sectional study examines patients鈥� out-of-pocket costs with and without rebate pass-through to point-of-sale prices for cancer drugs under Medicare Part D.

This economic evaluation examines the prices of cancer drugs on initial marketing and postlaunch prices and any association with clinical benefit.

This Viewpoint discusses policies the Biden administration can enact to reduce costs, including benchmarking Medicare Part B drug payments to the lowest price paid in similar countries, preventing Part D plans from negotiating confidential rebates with manufacturers, and patent reform to promote generic drug use.

This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

This Viewpoint discusses the appropriateness of existing US Food and Drug Administration regulatory pathways for artificial intelligence (AI) and machine learning (ML) software in health care, and proposes a lifecyle-based framework given the iterative nature of AI/ML algorithms, including prespecified 鈥渟afe harbor鈥� provisions for change and postapproval audits of accuracy.

This study characterizes price increases exceeding inflation between 2012 and 2017 for protected-class drugs (antineoplastics, antiretrovirals, antidepressants, antipsychotics, anticonvulsants, and immunosuppressants for transplant patients) that would lead to their exclusion from Medicare Part D coverage based on excessive cost under a 2018 CMS rule intended to facilitate more effective price negotiations.

This Viewpoint evaluates new transparency policies in cancer research and drug development.

This analysis of 75 brand-name drugs uses Medicare data to estimate the costs of proposed Medicare Part B and Part D reforms on total drug spending and patient cost-sharing for prescription drugs.

This cohort study evaluates the characteristics, completion rate, and transparency of study design and results for mandatory pediatric postmarketing studies required under the Pediatric Research Equity Act.